KI and MSD in patient-centred research collaboration

Denna sida på svenska

In January 2017, Karolinska Institutet entered a five-year research collaboration with pharmaceutical company MSD, a subsidiary of Merck and Co. Inc. The aim of the venture is to improve conditions for clinical research in the future and support product development by encouraging patient-centred studies – that is, studies on how approved drugs work in the real clinical world, a concept known as Real World Evidence.

This strategic collaboration agreement, which was signed in 2016, will bring KI revenues of USD 1 million a year for five years. The agreed setup is that while MSD contributes funds and specialist expertise, KI supplies a corresponding value in research capacity and human resources.